GlassScriptPhysician profile
Grayson Gremillion
NPI 1962701854
$4,136.82
in general payments reported to CMS, 2019-2025
22 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $126 · 2021: $412 · 2022: $1,129 · 2023: $578 · 2024: $651 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.03 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,127.14 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $606.64 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $438.09 | 2020-2025 | Dupixent |
| Medtronic, INC. | $372.98 | 2022-2024 | Propel, Nuvent |
| Acelrx Pharmaceuticals, INC. | $220.77 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $195.80 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Optinose US, INC. | $157.07 | 2019-2022 | |
| Abbvie INC. | $149.27 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $139.13 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $128.17 | 2022 | |
| Galderma Laboratories, L.P. | $109.84 | 2024 | |
| Inspire Medical Systems, INC. | $106.10 | 2024-2025 | Inspire |
| Pfizer INC. | $88.36 | 2025 | |
| Aerin Medical INC. | $51.89 | 2025 | |
| Genentech USA, INC. | $44.19 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $39.93 | 2022-2023 | Xpress Ent Dilation System |
| Medtronic USA, INC. | $39.29 | 2020 | |
| Hikma Pharmaceuticals USA | $34.45 | 2023-2024 | Ryaltris |
| Amgen INC. | $34.00 | 2025 | |
| Sanofi-Aventis U.S. LLC | $23.28 | 2021 | |
| Aytu Biopharma, INC. | $16.66 | 2019 | |
| Merck Sharp & Dohme LLC | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grayson Gremillion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.